


HOST-MICROBE INTERACTIONS

DAO does it

Nat. Microbiol. **1**, 16125 (2016)

NATURE MICROBIOLOGY



D-amino acids (D-aa) are not incorporated into proteins by ribosomes but function as signaling molecules, such as in mammalian neurotransmission, and as regulators of bacterial cell wall formation. Although bacteria have not been shown to produce D-aa previously, secretion of D-aa by commensal bacteria may affect host physiology. To test this, Sasabe *et al.* looked for D-aa and the D-aa-metabolizing enzyme DAO in the intestines of germ-free (GF) mice and mice free of only certain pathogens (SPF). The caeca of SPF mice expressed DAO and contained D-Ala, D-Asp, D-Glu and D-Pro, at levels much higher than in GF mice, which contained only relatively low levels of D-Asp. As well, DAO was expressed in the small intestine of SPF mice, secreted by enterocytes and goblet cells, and to a much lesser extent in GF mice. Luminal, mucosal and intraepithelial concentrations of D-ala were higher in DAO-mutant mice. The authors also found that DAO is bactericidal against several enteric pathogens, including *Vibrio cholerae*, *in vitro*, through the

production of H<sub>2</sub>O<sub>2</sub> from oxidation of D-aa. Also, a microbiome analysis showed that the overall intestinal microbiota composition is altered in the absence of DAO. These results suggest that the microbiota influences the production of DAO in the intestine, playing a general role in protection of the mucosal surface. MB

TRANSCRIPTIONAL REGULATION

Stuck in traffic

Mol. Cell **63**, 433–444 (2016)


Kin28 is a kinase within the yeast TFIIF complex. Some evidence indicates a role for Kin28 in regulating transcription initiation and elongation through phosphorylation of the C-terminal domain of RNA polymerase II (Pol II), but reversible Kin28 inhibitor studies revealed minor effects on cellular viability and mRNA synthesis, suggesting that a low level of Kin28 activity may be sufficient for transcriptional initiation. Rodriguez-Molina *et al.* proposed that irreversible/covalent inhibition might reduce Kin28 activity levels below this threshold and used a chemical-genetic approach to engineer mutations in the Kin28 ATP-binding pocket to enable binding by an ATP analog containing a thiol-reactive chloromethyl-ketone moiety (CMK). Yeast strains expressing this Kin28 irreversible-inhibitor-sensitized allele (*kin28is*) with CMK exhibited cellular lethality and greatly reduced serine phosphorylation in the C-terminal domain, resembling *KIN28* genetic mutants. Transcriptome analysis of *kin28is* with CMK revealed low levels of nascent mRNA, and Pol II tracking

studies exhibited a buildup of Pol II at 5' ends of protein-coding genes, revealing a role for Kin28 in promoting transcriptional elongation. Consistent with a defect in elongation activity, combining *kin28is* with a fast-processing RNA polymerase variant rescued the growth defects. Altogether, these studies present a structure-guided approach to irreversibly sensitizing a desired kinase and underscore the power of the covalent inactivation strategy to resolve biological questions. GM

PHOSPHOLIPIDS

How to flip a flippase

Proc. Natl. Acad. Sci. USA **113**, E4460–E4466 (2016)



In eukaryotes, the asymmetry of the plasma membrane is critical to its proper function, and this asymmetry is maintained by phospholipid flippase enzymes that selectively transport phospholipids from the exofacial to the cytofacial leaflet of the membrane. In yeast, the P4-ATPase Dnf1 is a phosphatidylcholine (PC) flippase and does not transport sphingomyelin (SM), even though the two have the same choline headgroup and highly similar fatty acyl chains. To understand how Dnf1 exerts such selectivity for its phospholipid substrates, Roland *et al.* used a directed evolution library of Dnf1 variants in a screen with fluorescently labeled PC and SM to identify flippase sequences capable of selecting for SM instead of PC. A single amino acid change at the cytofacial side of the transmembrane domain enabled Dnf1 to select for the sphingosine backbone of SM over the glycerol backbone of PC. Homology modeling and additional mutagenesis further elucidated how this position, along with others nearby in the exit-gate region of the protein, discriminates between various phospholipid backbones as well as different headgroups. The insights into selectivity afforded by this study suggest how substrate phospholipids are coordinated by the exit gate and should enable the design of new substrate-specific flippases for future studies of membrane asymmetry. CD

Written by Mirella Bucci, Caitlin Deane & Grant Miura

PROTEASOMES

Attack of cancer drugs

Science **353**, 594–598 (2016)

High-resolution structures of the human 20S proteasome reveal four coaxially stacked heteroheptameric rings, with the two inner rings containing the proteolytic active sites. Proteasome structures in complex with small-molecule inhibitors have yet to enable definition of the inhibition details at an atomic level. Using a newly developed workflow for purification and crystallization of human 20S proteasomes, Schrader *et al.* solved X-ray structures of the proteasome in complex with six inhibitors, including bortezomib, a drug used to treat multiple myeloma. The structures with two epoxyketones, oprozomib and dihydroeponemycin, revealed a 1,4-oxazepane (seven-membered) ring structure formed by nucleophilic attack of the active site threonine amine moiety to the compound epoxide β-carbon. This is notably different from the 1,4-morpholine ring structure and attack by the epoxide α-carbon that had been proposed in previous structural studies. The structures with these epoxyketones, the ketoaldehyde Z-LLY-ketoaldehyde, and three boronic inhibitors also define a proton-shuttling role for a water molecule both in catalysis of peptide cleavage and in the cyclization step of the inhibition reaction, findings that were corroborated by enzyme kinetics and cluster quantum chemical calculations. These findings refine the proteasome active site mechanism and suggest that the new workflow could allow for the development of novel active site inhibitors. MB